Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Gaseous nitric oxide-sequestering products and processes of preparing same

a technology of gaseous nitric oxide and products, applied in the field of medical products, can solve the problems of increasing the risk of infection, and constant risk to any healthy person, so as to reduce the pressure in the chamber

Inactive Publication Date: 2013-03-28
ENOX BIOPHARMA INC
View PDF8 Cites 20 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The invention relates to a method for reducing pressure in an enclosure to prevent damage to sensitive components. The method can involve gradually decreasing the pressure and can lead to a significant reduction in oxygen and humidity levels. This can help to create a safer and more controlled environment for sensitive components.

Problems solved by technology

Infection is a constant risk to any healthy person, and poses even a higher risk to hospitalized patients.
The risk of infection is further increased when the natural infection barriers of skin or other epithelial surfaces are breached during a surgical procedure, and / or otherwise in cases where bacteria normally present on the skin or in the air is allowed to access the interior surfaces of the body.
While medical devices that comprise metal, glass or other heat-stable materials can be treated with steam (autoclave) or hot air, the use of various polymers and plastics in medical devices may render heat-dependent sterilization unsuitable.
However, regardless of the method of sterilization, the medical device is only sterile until it is exposed to a non-sterile environment.
Contamination may even occur in a surgical environment.
CAB carries with it a 2.8-fold increased risk of death and results in bacteremia in approximately 3% of patients, constituting a serious complication.
CAB is difficult to treat with current antimicrobial strategies because of the antibiotic resistance biofilm that forms from free-floating bacteria that adhere to the surface of catheters and colonize them.
Catheterization also disrupts the uroepithelial mucosa, exposing new binding sites for bacterial adhesins.
However, silver oxide catheters were not associated with a statistically significant reduction in CAB, and other meta-analyses have similarly concluded that silver oxide coated catheters are ineffective.
However, nitrofurans have been demonstrated to be ineffective against most strains of Pseudomonas aeruginosa, and they do not inhibit viruses or fungi.
Nitrofurazone catheters are also very expensive.
However, orally-administered azoles such as fluconazole may be associated with side effects, such as GI intolerance and headache, and sometimes rash and liver toxicity [Nyirjesy, 2008, supra].
However, women with chronic or persistent yeast infections (RVVC) are less likely to respond to shorter treatment regimens, and symptomatic relapse occurs in more than half of RVCC cases within a short time of treatment cessation.
Multiple-day treatment regimens are more effective in women prone to RVVC and in certain populations, but the inconvenience of these regimens may negatively impact treatment compliance and satisfaction, symptom control, and quality of life.
Furthermore, single-dose oral or intravaginal therapy is limited in its efficacy to the treatment of mild to moderate infections.
Oral azoles are also contraindicated during pregnancy, are ineffective in vaginitis caused by C. glabrata, and may be associated with side effects such as GI intolerance, headache, and more rarely, rash and liver toxicity.
High rates of recurrence and lack of symptom resolution indicate that the primary treatment of BV with antibiotics may not be completely effective.
In addition, antibiotic resistance becomes a potential issue facing continued antibiotic treatment of BV, as well as possible changes to the composition of the normal flora of the vagina.
Forty-two percent of women with recurrent vaginal infections have been reported to resort to alternative therapies, such as probiotics or homeopathy, dietary restriction of sugars and inclusion of yogurt, and hormonal manipulation with depot medroxyprogesterone and desensitization therapy, to prevent recurrences, yet, support for the efficacy of these methodologies are sparse and often lack methodological quality and / or sufficient data.
However, nitric oxide is rather complicated for use as a gas.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Gaseous nitric oxide-sequestering products and processes of preparing same
  • Gaseous nitric oxide-sequestering products and processes of preparing same
  • Gaseous nitric oxide-sequestering products and processes of preparing same

Examples

Experimental program
Comparison scheme
Effect test

example 1

NO-Impregnated Silicone Catheters

[0442]Six-mm diameter Folysil® silicone Foley catheters, (catalog no. AA6118; Coloplast® Corp. Minneapolis, Minn., USA) (Folysil® and Coloplast® are registered trademarks of Coloplast A / S, Humlebaek, Denmark) were aseptically cut into 2-cm sections and inoculated by immersion in 2 ml of one of 103 CFU / ml, 105CFU / ml, or 108 CFU / ml E. coli. inocula for 30 minutes. Inoculated catheter sections were subsequently dosed with 20,000 parts per million of nitric oxide (at a flow rate of 30 cc / minutes) during 1, 5, 15, 30, 60 or 120 minutes, using the general procedure I described hereinabove. Control catheter sections were not impregnated with nitric oxide, but were stored in sterile sealed vials.

[0443]The nitric oxide-treated and untreated catheter segments were then immersed separately in 2 ml media and then incubated for 8 hours at 37° C. Aliquots of the incubation media were plated and numbers of CFU counted. Bacterial loads were calculated as CFU per ml....

example 2

NO-Impregnated Silicone Catheters

[0447]A commercially-available catheter, such as a six-mm diameter Folysil® silicone

[0448]Foley catheters, (catalog no. AA6118; Coloplast® Corp. Minneapolis, Minn., USA) is aseptically cut into 2-cm sections and inoculated by immersion in 2 ml of one of 103 CFU / ml, 105 CFU / ml, or 108 CFU / ml E. coli. inocula for 30 minutes. Inoculated catheter sections are subsequently dosed with nitric oxide using the general procedure II described hereinabove. Control catheter sections are not impregnated with nitric oxide, but are stored in sterile sealed vials.

[0449]The nitric oxide-treated and untreated catheter segments are then immersed separately in 2 ml media and incubated for 8 hours at 37° C. Aliquots of the incubation media are plated and numbers of CFU counted. Bacterial loads are calculated as CFU per ml.

[0450]Catheters impregnated with NO using general procedure II are found to eradicate bacteria at all of the tested bacteria concentrations. Sterilizati...

example 3

Nitric Oxide Loading in NO-Impregnated Catheters

[0451]Six-mm diameter Folysil® silicone Foley catheters were aseptically cut into 2-cm sections and exposed to nitric oxide for 1, 5, 10, 20, 40, 60, 120, 180 or 240 minutes, using general procedure I as described hereinabove. The samples were then immersed in doubly-distilled water and after 1 hour were assayed for nitrates and nitrites, as described hereinabove. All calculations were done per 1 cm of catheter.

[0452]FIG. 2 presents a plot of nitrite in μmol per cm of catheter relative to dosing time.

[0453]Table 2 presents the raw data of release of nitrates and nitrites from nitric oxide dosed catheter sample over varying dose times, wherein “Abs.” denotes absorbance, and “Abs average” denotes the average absorbance measured from duplicate sampling.

TABLE 2NO2conc.μmol NO2NOTimeAbsNO2inμmol / ppm / (min)Abs.Abs.average(μM)solutioncmcm10.0660.0690.0725.960.080.040.3950.2750.2740.27105.580.320.161.58100.3980.3640.38146.540.440.222.19200.4910...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
pressureaaaaaaaaaa
time periodaaaaaaaaaa
humidityaaaaaaaaaa
Login to View More

Abstract

A process of preparing articles having gaseous NO sequestered therein is disclosed, as well as articles prepared thereby. Also disclosed are articles having gaseous NO sequestered therewithin and having reduced amount of oxygen-containing and / or nitrogen-containing reactive species. Also disclosed are processes of preparing packaged articles having a non-gas permeable package that comprises gaseous NO therein and packaged articles made therefrom. Also disclosed are charging devices which can be utilized in the above-described processes. The articles prepared by the above-described processes are preferably medical devices such as indwelling catheters, intubation devices and tampons. Tampons having sequestered therein gaseous NO, uses thereof and processes of preparing same are also disclosed.

Description

FIELD AND BACKGROUND OF THE INVENTION[0001]The present invention, in some embodiments thereof, relates to medical products and, more particularly, but not exclusively, to products having gaseous nitric oxide (NO) sequestered therein, to processes and systems for producing such products and to uses thereof.[0002]Infection is a constant risk to any healthy person, and poses even a higher risk to hospitalized patients. Infections which are a result of treatment in a hospital or a healthcare service unit are often termed nosocomial infections. The risk of infection is further increased when the natural infection barriers of skin or other epithelial surfaces are breached during a surgical procedure, and / or otherwise in cases where bacteria normally present on the skin or in the air is allowed to access the interior surfaces of the body.[0003]Nosocomial infections occur even when good hygiene and sterile technique is followed, although the incidence is reduced. Despite even the most rigor...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): B65D25/00B65B5/00
CPCA61L15/22A61L15/46A61L27/14A61L27/54A61L28/0007A61L28/0038B65D25/00A61L29/16A61L31/04A61L31/16A61L2300/114B65B5/00A61L29/04A61P15/02
Inventor AV-GAY, YOSSEFMILLER, CHRISTOPHER C.BOHBOT, DEBORAHREGEV-SHOSHANI, GILLY
Owner ENOX BIOPHARMA INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products